Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. - Wikidata - wikimedia - TriplyDB

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.

http://www.wikidata.org/entity/Q45416568

about

The evolving roles and controversies of radiotherapy in the treatment of glioblastoma Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions DNA methylation biomarkers: cancer and beyond The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis Survival in glioblastoma: a review on the impact of treatment modalities.Treatment of glioblastoma in elderly patients.The rs16906252:C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort.MGMT promoter methylation correlates with an overall survival benefit in Chinese high-grade glioblastoma patients treated with radiotherapy and alkylating agent-based chemotherapy: a single-institution study.Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM)ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma.Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response Management of elderly patients with gliomas Role of MGMT as biomarker in colorectal cancer.Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis.Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis.Predictive value of MGMT promoter methylation status in Asian and Caucasian patients with malignant gliomas: a meta-analysis Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation.MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.MGMT testing allows for personalised therapy in the temozolomide era.Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis Pro-apoptotic effects of rHSG on C6 glioma cells.MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas.The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain Personalized treatment strategies in glioblastoma: MGMT promoter methylation status.High-grade glioma in elderly patients: can the oncogeriatrician help?Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients.Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.Patterns of diagnostic marker assessment in adult diffuse glioma: a survey of the European Confederation of Neuropathological Societies (Euro-CNS).EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.Molecular markers of glioma: an update on recent progress and perspectives.Imaging genomic mapping in glioblastoma.

P2860

Q26746622-1C389511-D689-46A9-9098-3496038D85FF Q26795767-120EC0E3-CBCB-4C9B-AFE5-BDD5F552E925 Q26996421-8F1F96ED-1043-4DDC-948C-08C2815701D1 Q27853156-83FF106D-9091-4FB7-A173-E89BD8E2EE93 Q28074595-CFB05A4E-5681-4C76-8032-66DDB390F96A Q30251810-776DF391-D8C3-4362-9BD8-FCEC38B14B03 Q30838145-481B9639-817E-418C-B4D5-910750F7DAD6 Q33757960-59894A7A-80CE-41C1-8E3B-BF22A29D2A52 Q34166477-80DB1236-1DB6-4A08-8F90-7161559C88AC Q34168829-AA175560-7679-4412-8272-B0D32E32E669 Q34256198-3BD29ABD-AC66-4353-A45A-354D3E048DCA Q34325808-8499F08E-1EF1-4030-8ADE-6057FF4A0C16 Q34478948-66D0E73A-5C1E-47F7-BAFF-8EA3BB977705 Q34525704-7DB5A57D-200E-4D18-A169-BB74B93A11A1 Q34641001-CCB0B827-6214-43EB-B616-A3539FB289E8 Q34706115-76A9D306-DF0A-45F8-8E45-E6B56501198B Q35004927-89FEF369-9724-4B29-91A3-CFA5C1F63F76 Q35638372-6730BD48-526B-4C23-8885-C7B8EC1E0134 Q35679476-F65E0040-123C-4E4B-AAED-E8244A377399 Q35741879-775667FF-306B-4C16-A71C-A60BDA8CB10D Q35803479-FB6C48DF-9FA2-4800-B9BB-A692E468FF7C Q35815273-3424F6CF-E9C6-4F1C-A847-3241F49F90DF Q35827916-8B0B1552-9F96-4EEB-8E96-69BCB1DFC842 Q36107360-A54BB348-B331-4B9C-B52A-484CCDC2BDCE Q36124303-69A81449-4F65-4B70-BE8C-F6E0E6D824EB Q36240860-70637DAE-3A1C-4D00-A851-7CE44FDD9453 Q36288503-653427A8-527C-4155-9C58-007CB31234E9 Q36289595-A4294388-3E70-4DCE-94AE-C63097D6FA0E Q36299167-E41ED47F-FF0A-4AB7-9B61-316A43071DE2 Q36344709-D254787D-583D-4E50-9FD2-4683FB401BF3 Q36542980-1CBBB865-3575-4F8E-9EA4-2AB7CA61BF29 Q36866021-70861001-8DE9-4171-8C35-BF84B68EB001 Q37221207-73E0FB05-0BC6-4BDA-A50C-09BD2E069C3F Q37388217-59053A2D-FE2F-4040-B0AD-4D5A9E92F733 Q37526270-9FAFDAD1-1AD9-4D78-B19F-2D2C329AC061 Q37641708-0ABB52E2-FDBE-4E97-B24F-29B72768C506 Q37644692-8E7FA96A-E487-4D55-B515-4A51402EB78A Q37660295-98231FBC-4B46-4C47-A5C6-885348C011AD Q38050966-098B8AED-241F-44C1-9646-ECCECD85B14F Q38120474-EBA9EEF7-28CF-41B0-A969-6C355D1C9DF1

P2860

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.

http://www.wikidata.org/entity/Q45416568

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.

@en

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.

@nl

type

label

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.

@en

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.

@nl

prefLabel

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.

@en

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.

@nl

P1433

Q45416568-85DDD902-9E3B-4A75-9C49-A05998227933

P1476

Q45416568-56C54799-F48E-4268-B0C0-0991B50AF0A3

P2093

Q45416568-085CCB42-9C24-49B0-8CF2-605D866EA059

Q45416568-81942B38-A459-4462-8120-9835DFE36785

Q45416568-9A414390-101E-4D63-92B3-9257BEC8AB52

Q45416568-9F56C274-8150-40D3-9AB3-027A74407C53

Q45416568-9F8497A7-4668-47BB-8B41-055C65ED07A1

Q45416568-A0882961-8E5C-4589-B012-997FC6E75186

Q45416568-F1CE2308-5362-47A0-9054-47B1519AEAEB

Q45416568-FB6487D8-6BFE-4C7C-B2BC-F0D7E5A9C8F1

P304

Q45416568-244146F7-C316-46E6-B8EF-0774E5811696

P31

Q45416568-1084C3EC-488E-41A6-8C88-0BC1B0245944

P356

Q45416568-7A773EB8-0190-4272-A3B9-E2E3E31D98C5

P433

Q45416568-F6306884-B4BB-463B-8411-EAF5F3D95CC8

P478

Q45416568-2CC6EEA4-A5CC-44DF-AC22-49142BF74F97

P50

Q45416568-3162E264-109F-4CA7-ADE1-B41451B45322

Q45416568-6D42C0EF-6C5E-4229-8F93-23B4DA094581

Q45416568-D90C7C6E-DC40-4D3B-9A03-9D9D32136D29

Q45416568-E7B66834-D7E4-4553-BD0F-74C48D3B8EA7

P577

Q45416568-7D08C9C5-5AE0-4640-AE61-117525A691A6

P5875

Q45416568-A4C34FE5-D369-40D7-97F4-84C16FE430A9

P698

Q45416568-361ABFFA-489B-4320-A2BD-5F1600346DDF

P356

P1433

International Journal of Cancer

P1476

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.

@en

P2093

Bettina Hentschel

http://www.w3.org/2001/XMLSchema#string

Gabriele Schackert

http://www.w3.org/2001/XMLSchema#string

German Glioma Network

http://www.w3.org/2001/XMLSchema#string

Manfred Westphal

http://www.w3.org/2001/XMLSchema#string

Markus Loeffler

http://www.w3.org/2001/XMLSchema#string

Matthias Simon

http://www.w3.org/2001/XMLSchema#string

Oliver Schnell

http://www.w3.org/2001/XMLSchema#string

Torsten Pietsch

http://www.w3.org/2001/XMLSchema#string

P304

1342-1350

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.27385

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P50

Guido Reifenberger

P577

2012-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51852051

http://www.w3.org/2001/XMLSchema#string

P698

22139906

http://www.w3.org/2001/XMLSchema#string